Market Cap 181.30M
Revenue (ttm) 794,000.00
Net Income (ttm) -37.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,159
Avg Vol 115,906
Day's Range N/A - N/A
Shares Out 13.89M
Stochastic %K 68%
Beta 1.50
Analysts Strong Sell
Price Target $25.60

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617-430-5595
Address:
300 Fifth Avenue, Waltham, United States
Estimize
Estimize Nov. 4 at 11:09 PM
Wall St is expecting -1.96 EPS for $CBIO Q3 [Reporting 11/12 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c
0 · Reply
Raxothus
Raxothus Oct. 16 at 7:40 PM
EOD CONTINUATION WATCHLIST – 10/16/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $SBFM – 9.2x volume, 3.1% VWAP stretch, micro float (4.6M) 3.5% open-to-current with 3.5% late push, RSI 63.8. Watching breakout > 2.39 for continuation. $NXTC – 6.9x volume, 14.6% VWAP stretch, micro float (1.9M) 23.9% open-to-current with 11.4% late push, RSI 71.3. Watching breakout > 8.50 for continuation. $BIAF – 3.1x volume, 10.9% VWAP stretch, micro float (0.9M) 11.8% open-to-current with 2.4% late push, RSI 65.6. Watching breakout > 3.37 for continuation. $LGPS – 3.1x volume, 10.3% VWAP stretch, micro float (6.3M) 17.5% open-to-current with 2.2% late push, RSI 58.5. Watching breakout > 1.20 for continuation. $CBIO – 3.5x volume, 5.2% VWAP stretch, micro float (7.5M) 10.5% open-to-current with 0.8% late push, RSI 56.2. Watching breakout > 12.55 for continuation. #eod #vwap #momentum #smallcaps #daytrading #continuationsetups #powerhourwatch
1 · Reply
slick3333
slick3333 Oct. 13 at 7:24 PM
$CBIO holding steady oh wait doesn’t update
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 10:39 PM
Keep a close watch on CMCT! ITS MOVING!! $JZ $JFBR $GCTK $CBIO <
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 8:47 PM
Keep a close watch on CMCT! $JFBR $HOLO $ONCO $CBIO II
0 · Reply
DreamCreator
DreamCreator Oct. 3 at 12:35 AM
0 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 27 at 3:39 AM
IVDA would it surprise me if it was $30+? no it would not, and Nobody's paying attention to and that's exactly how big runners begin. AI, robotics, and drone surveillance in one microcap. Trading at rock bottom. Float is small. Tech is real. Squeeze potential is enormous.. $SRNE $CBIO $KTRA $DCTH $HCDI
1 · Reply
slick3333
slick3333 Sep. 27 at 2:22 AM
$CBIO wonder when they will ever update the price
0 · Reply
slick3333
slick3333 Sep. 27 at 2:22 AM
$GLYC long forgotten $CBIO
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:36 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $CDIO $CBIO $THCH $GECC $RDNW
0 · Reply
Latest News on CBIO
Crescent Biopharma to Present at September Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 2 months ago

Crescent Biopharma to Present at September Investor Conferences


Crescent Biopharma: Chasing The Summit Hype

Aug 18, 2025, 11:33 AM EDT - 3 months ago

Crescent Biopharma: Chasing The Summit Hype


Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 28, 2025, 7:30 AM EDT - 7 months ago

Crescent Biopharma Appoints David Lubner to Board of Directors


GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

May 9, 2024, 3:17 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript


GlycoMimetics: Is No News Bad News?

Apr 30, 2024, 7:42 AM EDT - 1 year ago

GlycoMimetics: Is No News Bad News?


GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 10:27 AM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript


GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21, 2024, 5:47 PM EDT - 1 year ago

GlycoMimetics Can Become A Game Changer In Blood Cancers


GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 12:24 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript


GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 1:09 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript


Estimize
Estimize Nov. 4 at 11:09 PM
Wall St is expecting -1.96 EPS for $CBIO Q3 [Reporting 11/12 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c
0 · Reply
Raxothus
Raxothus Oct. 16 at 7:40 PM
EOD CONTINUATION WATCHLIST – 10/16/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $SBFM – 9.2x volume, 3.1% VWAP stretch, micro float (4.6M) 3.5% open-to-current with 3.5% late push, RSI 63.8. Watching breakout > 2.39 for continuation. $NXTC – 6.9x volume, 14.6% VWAP stretch, micro float (1.9M) 23.9% open-to-current with 11.4% late push, RSI 71.3. Watching breakout > 8.50 for continuation. $BIAF – 3.1x volume, 10.9% VWAP stretch, micro float (0.9M) 11.8% open-to-current with 2.4% late push, RSI 65.6. Watching breakout > 3.37 for continuation. $LGPS – 3.1x volume, 10.3% VWAP stretch, micro float (6.3M) 17.5% open-to-current with 2.2% late push, RSI 58.5. Watching breakout > 1.20 for continuation. $CBIO – 3.5x volume, 5.2% VWAP stretch, micro float (7.5M) 10.5% open-to-current with 0.8% late push, RSI 56.2. Watching breakout > 12.55 for continuation. #eod #vwap #momentum #smallcaps #daytrading #continuationsetups #powerhourwatch
1 · Reply
slick3333
slick3333 Oct. 13 at 7:24 PM
$CBIO holding steady oh wait doesn’t update
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 10:39 PM
Keep a close watch on CMCT! ITS MOVING!! $JZ $JFBR $GCTK $CBIO <
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 8:47 PM
Keep a close watch on CMCT! $JFBR $HOLO $ONCO $CBIO II
0 · Reply
DreamCreator
DreamCreator Oct. 3 at 12:35 AM
0 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 27 at 3:39 AM
IVDA would it surprise me if it was $30+? no it would not, and Nobody's paying attention to and that's exactly how big runners begin. AI, robotics, and drone surveillance in one microcap. Trading at rock bottom. Float is small. Tech is real. Squeeze potential is enormous.. $SRNE $CBIO $KTRA $DCTH $HCDI
1 · Reply
slick3333
slick3333 Sep. 27 at 2:22 AM
$CBIO wonder when they will ever update the price
0 · Reply
slick3333
slick3333 Sep. 27 at 2:22 AM
$GLYC long forgotten $CBIO
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:36 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $CDIO $CBIO $THCH $GECC $RDNW
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 11 at 9:03 AM
$SMMT at $14B, this stock remains overvalued. $BNTX, $CMPX, $CBIO and/or even $MRK are the better investments in this space imho.
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 11 at 7:19 AM
$CBIO Outstanding article that hits the mark on CBIO's current state. So if you want to refresh your CBIO insights or learn about CBIO from scratch, this is a must read. https://beyondspx.com/quote/CBIO/analysis/crescent-biopharma-unlocking-oncology-s-next-frontier-with-bispecifics-and-adcs-nasdaq-cbio
0 · Reply
MorenitaScorp
MorenitaScorp Sep. 10 at 12:25 PM
$CBIO ⌚️
0 · Reply
RJedi
RJedi Aug. 29 at 3:23 PM
$CBIO @Stocktwits can we get the CBIO ticker updating. Thanks
0 · Reply
JarvisFlow
JarvisFlow Aug. 27 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Crescent Biopharma ( $CBIO ), setting the rating to Buy with a target price of 25.
0 · Reply
JarvisFlow
JarvisFlow Aug. 25 at 11:30 AM
Jefferies has updated their rating for Crescent Biopharma ( $CBIO ) to Buy with a price target of 26.
0 · Reply
DavisDivergence
DavisDivergence Aug. 23 at 8:31 AM
$CBIO Catalyst Biosciences Inc is a clinical stage biotech with pipeline restructuring
0 · Reply
Estimize
Estimize Aug. 14 at 10:00 AM
Wall St is expecting -1.96 EPS for $CBIO Q3 [Reporting 11/12 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Aug. 11 at 11:00 AM
HC Wainwright & Co. updates rating for Crescent Biopharma ( $CBIO ) to Buy, target set at 25.
0 · Reply
ProfProfit
ProfProfit Aug. 6 at 10:53 PM
$CBIO what a pile of shit
0 · Reply
DonCorleone77
DonCorleone77 Jul. 31 at 11:40 AM
$CBIO Crescent Biopharma reports Q2 EPS ($4.93) -- Sees cash runway through 2027 -- Cash was $152.6 million as of June 30, 2025
0 · Reply